Edwards Lifesciences Corp
EW: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$45.00 | Jjjllw | Lxhhdvqls |
Edwards Lifesciences Secures US Regulatory Approval for Transcatheter Tricuspid Valve
Business Strategy and Outlook
Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical heart valves and minimally invasive valve therapy—one of the hottest areas in cardiac devices.